伊洛前列素治疗伴持续低灌注的严重脓毒性休克:双盲随机对照试验
这项多中心、双盲、随机对照试验纳入240例伴持续低灌注(毛细血管再充盈时间延长和/或皮肤花斑)的脓毒性休克成人,随机接受48小时静脉输注伊洛前列素或安慰剂,236例纳入分析。主要终点为随机化至第7天SOFA评分变化,伊洛前列素组中位变化-4(-7至7),安慰剂组-5(-8至5),中位差值1(95%CI 0-3,P=0.12)。第28天伊洛前列素组48例(42%)死亡,安慰剂组47例(39%)死亡(相对危险度1.08,95%CI 0.80-1.5)。结论为在伴持续低灌注的脓毒性休克患者中,伊洛前列素未降低器官衰竭严重程度。
要点
- 主要终点第7天SOFA评分变化:伊洛前列素组中位-4(-7至7)vs 安慰剂组-5(-8至5),中位差值1(95%CI 0-3,P=0.12),未达统计学显著。
- 第28天死亡率:伊洛前列素组48例(42%)vs 安慰剂组47例(39%),相对危险度1.08(95%CI 0.80-1.5)。
- 28天平均每日SOFA评分中位:伊洛前列素组11.2(7.4-15.9)vs 安慰剂组10.5(6.8-16.5),中位差值0.25(95%CI -1.1至1.8)。
- 28天无通气、无升压药、无肾脏替代治疗生存天数组间中位差值分别为0(0-0)、0(-1至1)、0(0-0)。
- 严重不良事件:伊洛前列素组15% vs 安慰剂组7%(P=0.06)。
适用人群与场景
- 成人脓毒性休克患者,伴持续低灌注,即毛细血管再充盈时间延长和/或皮肤花斑。
诊断标准与关键阈值
- 持续低灌注定义:毛细血管再充盈时间延长和/或皮肤花斑。
处置流程与药物剂量
- 伊洛前列素组:48小时静脉输注伊洛前列素;安慰剂组:48小时静脉输注安慰剂。
研究设计与关键结果
- 多中心、双盲、随机对照试验,240例随机化,236例纳入分析。
- 主要终点第7天SOFA评分变化中位:伊洛前列素组-4(-7至7)vs 安慰剂组-5(-8至5),中位差值1(95%CI 0-3,P=0.12)。
- 第28天死亡:伊洛前列素组48例(42%)vs 安慰剂组47例(39%),相对危险度1.08(95%CI 0.80-1.5)。
- 28天平均每日SOFA评分中位:伊洛前列素组11.2(7.4-15.9)vs 安慰剂组10.5(6.8-16.5),中位差值0.25(95%CI -1.1至1.8)。
- 28天无通气、无升压药、无肾脏替代治疗生存天数组间中位差值分别为0(0-0)、0(-1至1)、0(0-0)。
- 严重不良事件:伊洛前列素组15% vs 安慰剂组7%(P=0.06)。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在伴持续低灌注的脓毒性休克成人中,48小时静脉输注伊洛前列素未降低第7天SOFA评分变化,未改善器官衰竭严重程度。
- 第28天死亡率伊洛前列素组42% vs 安慰剂组39%,相对危险度1.08(95%CI 0.80-1.5),未达统计学显著。
- 严重不良事件伊洛前列素组15% vs 安慰剂组7%(P=0.06)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Preclinical and preliminary clinical data suggest that iloprost may improve tissue perfusion in septic shock. However, its effect on organ failure remains unclear. Objectives: To investigate whether iloprost provides organ protection in septic shock with hypoperfusion. Methods: In this multicenter, double-blind, randomized controlled trial, adults with septic shock and persistent hypoperfusion (i.e., increased capillary refill time and/or skin mottling) were randomized to receive a 48-hour intravenous infusion of iloprost or placebo. The primary outcome was the change in the Sequential Organ Failure Assessment (SOFA) score from randomization to Day 7. Secondary outcomes included mortality at Day 28, organ support-free days by Day 28, and mean daily SOFA score. Measurements and Main Results: A total of 240 patients were randomized, and 236 were included in the analysis. Median (IQR) changes in SOFA score were -4 (-7 to 7) in the iloprost group and -5 (-8 to 5) in the placebo group (median difference, 1; 95% CI, 0-3; P = 0.12). At 28 days, 48 patients (42%) had died in the iloprost group and 47 (39%) had died in the placebo group (relative risk, 1.08; 95% CI, 0.80-1.5). The median average SOFA score was 11.2 (7.4-15.9) in the iloprost group, compared with 10.5 (6.8-16.5) in the placebo group (median difference, 0.25; 95% CI, -1.1 to 1.8). Median (95% confidence interval) between-group differences in 28-day ventilation-, vasopressor-, and renal replacement therapy-free survival days were 0 (0-0), 0 (-1 to 1), and 0 (0-0), respectively. Severe adverse events occurred in 15% of patients in the iloprost group and 7% of patients in the placebo group (P = 0.06). Conclusions: Among patients with septic shock and persistent hypoperfusion, iloprost did not reduce the severity of organ failure. Clinical trial registered with www.clinicaltrials.gov (NCT03788837) and EudraCT (2018-001709-10).
参考来源
- Legrand M, Jullien E, Kimmoun A, et al. Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial. Am J Respir Crit Care Med. 2025. PMID: 40387381. doi:10.1164/rccm.202410-1924OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。